NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

               

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), December 20, 2024, 10:30 pm CET / 4:30 pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

BlackRock, Inc.

On December 19, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. Based on the notification, BlackRock, Inc. (together with its controlled undertakings) holds 1,124,630 voting rights, consisting of 1,122,658 shares and 1,972 equivalent financial instruments, representing 3.00% of the total number of voting rights on December 17, 2024 (37,427,265).

The notification dated December 18, 2024 contains the following information:

  • Reason for the notification:
    • Acquisition or disposal of voting securities or voting rights
    • Acquisition or disposal of financial instruments that are treated as voting securities
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • BlackRock, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Advisors, LLC (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Financial Management, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
    • BlackRock Fund Advisors (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
    • BlackRock Institutional Trust Company, National Association (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
    • BlackRock Investment Management (UK) Limited (with address at 12 Throgmorton Avenue, London, EC2N 2DL, U.K.)
    • BlackRock Investment Management, LLC (with address at 1 University Square Drive, Princeton, NJ, 8540, U.S.A.)
  • Date on which the threshold was crossed: December 17, 2024
  • Threshold that is crossed: 3%
  • Denominator: 37,427,265
  • Notified details:
A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
BlackRock, Inc.00 0.00% 
BlackRock Advisors, LLC1,038,3611,089,161 2.91% 
BlackRock Financial Management, Inc.06,167 0.02% 
BlackRock Fund Advisors446255 0.00% 
BlackRock Institutional Trust Company, National Association02,551 0.01% 
BlackRock Investment Management (UK) Limited1,0801,080 0.00% 
BlackRock Investment Management, LLC25,23423,444 0.06% 
Subtotal1,065,121 1,122,658 3.00% 
 TOTAL1,122,65803.00%0.00%



B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
BlackRock Fund AdvisorsSecurities Lent  2000.00%physical
BlackRock Financial Management, Inc.Contract Difference  1,7720.00%cash
 TOTAL  1,9720.01% 



 TOTAL (A & B)# of voting rights% of voting rights 
    1,124,6303.00% 
  • Full chain of controlled undertakings through which the holding is effectively held:



BlackRock, Inc.

BlackRock Finance, Inc.

Trident Merger, LLC

BlackRock Investment Management, LLC

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Holdco 3, LLC

BlackRock Cayman 1 LP

BlackRock Cayman West Bay Finco Limited

BlackRock Cayman West Bay IV Limited

BlackRock Group Limited

BlackRock Finance Europe Limited

BlackRock Investment Management (UK) Limited

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Holdco 4, LLC

BlackRock Holdco 6, LLC

BlackRock Delaware Holdings Inc.

BlackRock Institutional Trust Company, National Association

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Holdco 4, LLC

BlackRock Holdco 6, LLC

BlackRock Delaware Holdings Inc.

BlackRock Fund Advisors

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock, Inc.

BlackRock Finance, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Capital Holdings, Inc.

BlackRock Advisors, LLC

  • Additional information: The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going above 3%. Please note that the actual percentage in section 10 (A) is 2.99%. The form displays it as remaining at 3% due to the rounding of the form.



*

* *

Contact:

Nyxoah

John Landry, CFO



Attachment



EN
20/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

EQS-News: Nyxoah erhält Approvable Letter für sein Genio®-System von d...

EQS-News: Nyxoah SA. / Schlagwort(e): Sonstiges Nyxoah erhält Approvable Letter für sein Genio®-System von der FDA 26.03.2025 / 09:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Nyxoah erhält Approvable Letter für sein Genio®-System von der FDA Mont-Saint-Guibert, Belgien – 26. März 2025 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ein Medizintechnikunternehmen, das innovative Technologien zur Behandlung der obstruktiven Schlafapnoe („Obstructive Sleep Apnea“, OSA) mithilfe von Neurostimulation ...

 PRESS RELEASE

EQS-News: FDA Issues Nyxoah an Approvable Letter for its Genio® System

EQS-News: Nyxoah SA. / Key word(s): Miscellaneous FDA Issues Nyxoah an Approvable Letter for its Genio® System 26.03.2025 / 09:45 CET/CEST The issuer is solely responsible for the content of this announcement. FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administra...

 PRESS RELEASE

FDA Issues Nyxoah an Approvable Letter for its Genio® System

FDA Issues Nyxoah an Approvable Letter for its Genio® System INSIDE INFORMATIONREGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® syst...

 PRESS RELEASE

La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son système G...

La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son système Genio®   INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son Système Genio® Mont-Saint-Guibert, Belgique – 26 mars 2025, 8h00 CET / 3h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques innovantes pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui que la Food and Drug Administration (FDA) des États-Unis a émi...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli

ResearchPool Subscriptions

Get the most out of your insights

Get in touch